Literature DB >> 30241043

Strategies for immune evasion by human tumor viruses.

Kendra A Bussey1, Melanie M Brinkmann2.   

Abstract

Immune evasion is a hallmark of viral persistence. For the seven human tumor viruses to establish lifelong infection in their hosts, they must successfully control the host response to them. Viral inhibition of immune responses occurs at many levels. While some viruses directly target the pattern recognition receptors (PRR) of the innate immune system, they may also antagonize downstream effectors of PRR signaling cascades or activation of transcription, which would otherwise induce a type I interferon (IFN) and/or pro-inflammatory cytokine response. Secretion of IFN activates the type I interferon receptor (IFNAR) signaling pathway, which is also prone to viral inhibition. To evade the adaptive host response, viruses also target various mechanisms including antigen processing and presentation.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30241043     DOI: 10.1016/j.coviro.2018.08.015

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  4 in total

1.  Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy.

Authors:  Konstantinos Poulas; Konstantinos Farsalinos; Charilaos Zanidis
Journal:  Front Immunol       Date:  2020-06-11       Impact factor: 7.561

2.  Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection.

Authors:  Christoph B Messner; Vadim Demichev; Daniel Wendisch; Laura Michalick; Matthew White; Anja Freiwald; Kathrin Textoris-Taube; Spyros I Vernardis; Anna-Sophia Egger; Marco Kreidl; Daniela Ludwig; Christiane Kilian; Federica Agostini; Aleksej Zelezniak; Charlotte Thibeault; Moritz Pfeiffer; Stefan Hippenstiel; Andreas Hocke; Christof von Kalle; Archie Campbell; Caroline Hayward; David J Porteous; Riccardo E Marioni; Claudia Langenberg; Kathryn S Lilley; Wolfgang M Kuebler; Michael Mülleder; Christian Drosten; Norbert Suttorp; Martin Witzenrath; Florian Kurth; Leif Erik Sander; Markus Ralser
Journal:  Cell Syst       Date:  2020-06-02       Impact factor: 10.304

Review 3.  Subversion of Host Innate Immunity by Human Papillomavirus Oncoproteins.

Authors:  Irene Lo Cigno; Federica Calati; Silvia Albertini; Marisa Gariglio
Journal:  Pathogens       Date:  2020-04-17

4.  Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19.

Authors:  Athina Angelopoulou; Nikos Alexandris; Evangelia Konstantinou; Konstantinos Mesiakaris; Charilaos Zanidis; Konstantinos Farsalinos; Konstantinos Poulas
Journal:  Environ Res       Date:  2020-06-23       Impact factor: 6.498

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.